Insider Transactions in Q4 2025 at Nektar Therapeutics (NKTR)
Insider Transaction List (Q4 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 22
2025
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
21,667
+22.2%
|
-
|
|
Dec 22
2025
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+19.86%
|
-
|
|
Nov 25
2025
|
Mark Andrew Wilson Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
630
-2.84%
|
$34,020
$54.28 P/Share
|
|
Nov 25
2025
|
Jonathan Zalevsky Chief R&D Officer |
SELL
Open market or private sale
|
Direct |
1,157
-5.75%
|
$62,478
$54.28 P/Share
|
|
Nov 25
2025
|
Howard W Robin President & CEO |
SELL
Open market or private sale
|
Direct |
2,207
-3.91%
|
$119,178
$54.28 P/Share
|
|
Nov 21
2025
|
Mark Andrew Wilson Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,903
+7.89%
|
-
|
|
Nov 21
2025
|
Jonathan Zalevsky Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,666
+11.7%
|
-
|
|
Nov 21
2025
|
Howard W Robin President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
7,110
+11.19%
|
-
|